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Experimental studies have established the use of mesenchymal stem cells (MSC) as a can-
didate immunosuppressive therapy. MSC exert their immunomodulatory function through
the inhibition of CD4+ and CD8+ T cell proliferation. It is unknown whether MSC impair
the immunosuppressive function of regulatory T cells (Treg). In vitro and in vivo studies
suggest that MSC mediate their immunomodulatory effects through the induction ofTreg.
In this review we will focus on the interactions between MSC and Treg, and evaluate the
consequences of these cellular interplays for prospective MSC immunotherapy in organ
transplantation.
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INTRODUCTION TO MSC AND TREG
Since the discovery of mesenchymal stem cells (MSC) in bone
marrow by Friedenstein et al. (1970), researchers were able to
isolate these adherent cells from various postnatal and adult
tissue sources (Pittenger et al., 1999; Zuk et al., 2002; Hoog-
duijn et al., 2007; Antonucci et al., 2011). MSC are self-renewing
and capable of forming colonies while retaining their multilin-
eage differentiation potential. They are able to differentiate into
adipocytes, chondrocytes, osteoblasts, and myocytes (Pittenger
et al., 1999; de la Garza-Rodea et al., 2012). These features repre-
sent part of the criteria that deﬁne MSC (Dominici et al., 2006).
MSC are immunophenotypically characterized by the expres-
sion of the cell surface markers CD73, CD90, CD105, and
HLA-DRlow, and the absence of CD11b, CD14, CD19, CD34,
CD45, and CD79α. Interest in MSC for their use in transplan-
tation was fostered when it was ﬁrst discovered that MSC possess
T cell suppressive properties (Bartholomew et al., 2002). Inten-
sive research was undertaken to unravel the mechanisms by which
MSC exert their immunomodulatory functions. Besides CD4+
helper T cells and CD8+ cytotoxic T cells, activated B cells
and natural killer (NK) cells are also susceptible to the sup-
pressive activity of MSC (Corcione et al., 2006; Sotiropoulou
et al., 2006). Further, MSC hamper the maturation of den-
dritic cells (DC) through the downregulation of MHC class II
molecules and co-stimulatory molecules (Aggarwal and Pittenger,
2005; Jiang et al., 2005; Nauta et al., 2006). In addition to these
immunosuppressive effects, MSC also have immunosupportive
properties; they delay the apoptosis of neutrophils, preserving
them to be readily available to counter infections (Raffaghello
et al., 2008). Immunomodulation by MSC is mediated by cell–cell
contact and the release of soluble factors. Important mediators are
indoleamine 2,3-dioxygenase (IDO), transforming growth factor-
beta (TGF-β), interleukin-10 (IL-10), prostaglandin E2 (PGE2),
hepatocyte growth factor (HGF), human leukocyte antigen-G5
(HLA-G5), and nitric oxide (NO; Di Nicola et al., 2002; Meisel
et al., 2004; Groh et al., 2005; Batten et al., 2006; Nasef et al.,
2007; Sato et al., 2007; Hoogduijn et al., 2010a; Deuse et al.,
2011). The ability of MSC to exert their immunosuppressive
function requiresMSC activation in a pro-inﬂammatorymicroen-
vironment through the presence of cytokines like interferon-
gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-1α, and
IL-1β (Crop et al., 2010). Collecting in vivo data suggest that MSC
could be used as immunotherapy (Bartholomew et al., 2002; Popp
et al., 2008). In clinical studies MSC have successfully attenuated
graft-versus-host-disease (GvHD) after hematopoietic stem cell
transplantation (Le Blanc et al., 2004, 2008). Currently, research
groups strive to conﬁrm the safety and feasibility of MSC therapy
in solid organ transplantation (Hoogduijn et al., 2010b; Perico
et al., 2011).
Primarily T cells are targeted by the immunosuppressive
effect of MSC which raises the question, to what extent MSC
affect T cells with immunomodulatory properties. Regulatory
T cells (Treg) were ﬁrst characterized by Sakaguchi et al. (1995)
as activated CD4+ T cells expressing CD25, the IL-2 receptor
alpha-chain, which are involved in the maintenance of toler-
ance to self-antigens. Human Treg are commonly characterized
by their expression of the transcription factor forkhead box P3
(FOXP3) and the FOXP3 reciprocal expression of CD127, the
IL-7 receptor alpha-chain (Fontenot et al., 2003; Liu et al., 2006;
Seddiki et al., 2006); additional markers are the co-stimulatory
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molecules cytotoxic T lymphocyte antigen-4 (CTLA-4) and
the glucocorticoid-induced TNF receptor-related protein (GITR;
Read et al., 2000; Salomon et al., 2000; Takahashi et al., 2000;
McHugh et al., 2002; Shimizu et al., 2002). While a unique marker
for human Treg is yet to be identiﬁed, FOXP3 presents a reliable
marker for Treg in mice (Ziegler, 2006).
The importance of Treg in the maintenance of tolerance
is highlighted in humans suffering from immunodysregula-
tion polyendocrinopathy enteropathy X-linked syndrome (IPEX;
Bennett et al., 2001; Kobayashi et al., 2001). IPEX patients lack
functional Treg as a result of a point mutation in the Foxp3 gene
(Bacchetta et al., 2006). In other autoimmune diseases, the role
of Treg remains controversial (Buckner, 2010). The immunomod-
ulating nature of Treg made them interesting candidates for the
induction of transplantation tolerance. Indeed, Treg have been
reported to control alloreactivity by inhibiting the functionality
of cell types similar to those suppressed by MSC; Treg ham-
per the proliferation of CD4+ T cells, CD8+ T cells, and DC
(Velthuis et al., 2006; Bestard et al., 2007; Tang and Bluestone,
2008; Hendrikx et al., 2009a). Further, molecules associated with
the tolerogenic and suppressive function of Treg partially overlap
with those involved in MSC-mediated immunomodulation and
include IL-10, TGF-β, and heme oxygenase-1 (HO-1; Tang and
Bluestone, 2008). In addition, it has been hypothesized that Treg
are able to inﬂuence their target cells in a granzyme B-dependent
and perforin-dependent manner (Grossman et al., 2004; Gondek
et al., 2005). Results from different humanized mouse models
and clinical studies in patients with GvHD encourage the use
of freshly isolated or ex vivo expanded Treg (Trzonkowski et al.,
2009; Issa et al., 2010; Nadig et al., 2010; Brunstein et al., 2011;
Di Ianni et al., 2011). Despite the indication that Treg therapy
is promising and well tolerated in patients receiving stem cell
treatment, clinical information about the application of Treg in
solid organ transplantation is still lacking. However, Treg rep-
resent one of the immunomodulatory cell types whose clinical
safety is currently under investigation (McMurchy et al., 2011;
Schliesser et al., 2012).
Both MSC and Treg are able to inﬂuence the adaptive immune
system by utilizing similar and distinct mechanisms. There-
fore, it is of interest whether the overlapping mechanisms cause
interference of the immunomodulatory properties of both cell
types.
IN VITRO INTERACTION BETWEEN MSC AND TREG
Recently we investigated the interaction between MSC and Treg
in a transplantation setting (Engela et al., 2012). We found that
MSC derived from healthy kidney donors permitted the function
of Treg from healthy donors as well as Treg from renal transplant
patients. Vice versa, Treg did not hamper MSC function.
One of the ﬁrst indications that T cells with a regulatory
phenotype are unaffected by the suppressive capacities of MSC
was provided by Maccario et al. (2005). This group reported
that although autologous MSC and third-party MSC were able
to suppress the proliferation of CD4+ T cells and CD8+ T
cells in primary mixed lymphocyte cultures (MLC), after re-
stimulation in secondary MLC the numbers of CD4+ T cells
co-expressing CD25 and/or CTLA-4 increased. This indicates
an MSC-dependent preferential differentiation into T cells with
a regulatory phenotype. Similar observations were made by
Prevosto et al. (2007) after PBMC–MSC co-culture. In addi-
tion, IL-2 stimulation of PBMC in the presence of MSC also
led to elevated proportions of CD4+CD25+ cells (Aggarwal
and Pittenger, 2005). It has to be considered that due to lack
of appropriate markers no distinction could be made between
activated effector cells and Treg in these early research studies.
Employing newly discovered markers, Di Ianni et al. (2008) per-
formed an extensive study to shed light on the T cell population
that is most responsive to the MSC-stimulus for Treg gener-
ation. The largest numbers of CD4+CD25+FOXP3+CD127−
Treg were found when MSC were cultured with immunose-
lected CD3+CD45RA+ or CD3+CD45RO+ fractions. Co-culture
of MSC with different Treg populations such as CD4+CD25+
cells, CD4+CD25+CD45RA+ cells, and CD4+CD25+CD45RO+
cells maintained FOXP3 expression, CD127 downregulation, and
the immunosuppressive activities of Treg for about 2 weeks. In
the absence of MSC the Treg populations lost their suppressive
capacities during this period.
The apparent interplay between MSC and Treg in the allo-
suppression of T cell proliferation triggered researchers’ interest
in the factors and mediators involved. Although conﬂicting data
exist, it is the current opinion that key factors involved in Treg
induction by MSC are MSC-derived TGF-β and PGE2 (Prevosto
et al., 2007; English et al., 2009). TGF-β is a key regulator of
the initiation and maintenance of FOXP3 expression, and the
suppressive function of Treg (Chen et al., 2003; Fu et al., 2004).
PGE2 is an immunosuppressant that inhibits T cell mitogenesis
and the production of IL-2. TGF-β and PGE2 are constitutively
produced by MSC. Secretion of these two immunomodulatory
molecules can be increased through “MSC licensing,” the acti-
vation of MSC with TNF-α and IFN-γ which improves their
immunosuppressive capacity (English et al., 2007; Ryan et al.,
2007). MSC-derived PGE2 also exerts suppressive functions by
increasing the IL-10 production of macrophages and by limiting
monocyte differentiation into DC (Nemeth et al., 2009; Spag-
giari et al., 2009). It has also been reported that PGE2 induces
a regulatory phenotype in CD4+CD25− T cells by modulating
the expression of FOXP3 and therefore contributes to Treg func-
tion (Baratelli et al., 2005). In addition, cell–cell contact seems
to play a non-redundant role in the induction of Treg (English
et al., 2009). After culture of CD4+ cells with MSC, increases in
mRNA levels of CD25 and FOXP3 mRNA were only detected
when cells were in close proximity; when cells were separated
by a tissue culture insert, this effect was not observed. For
enhancement of FOXP3 expression in PBMC, however, direct
MSC–PBMC contact was not required. This suggests that cell–
cell contact between certain PBMC subpopulations contributes
to the FOXP3 expression and substitutes for MSC–CD4+ cell
contact interactions. Another factor inﬂuencing the immunomod-
ulatory effect of MSC on alloactivated T cells as well as the
expansion of CD4+CD25+FOXP3+ Treg is the soluble protein
HLA-G5 (Selmani et al., 2008). In the presence of anti-HLA-
G5 antibody, MSC-mediated immunosuppression was hampered.
Neutralization of the HLA-G5 protein led to a decrease in the
generation of CD4+CD25+FOXP3+ T cells. In addition, the
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tryptophan-catabolizing enzyme IDO was identiﬁed as a crucial
modulator of the immunosuppressive effect of MSC (Meisel et al.,
2004; Jurgens et al., 2009). Using a renal allograft model, Ge et al.
(2010) investigated whether MSC-driven T cell suppression is also
a consequence of the induction of Treg. Graft survival in untreated
kidney recipients was signiﬁcantly lower than graft survival in
mice after MSC treatment. Increased serum levels of kynure-
nine in MSC-treated allograft recipients indicated increased IDO
enzymatic activity and correlated with higher frequencies of
CD4+CD25+FOXP3+ Treg in recipient spleen and in the allo-
graft. In this model recipient treatment with IDO-knockout MSC
or the IDO inhibitor 1-methyl-tryptophan did not achieve graft
tolerance. Therefore, the expression of functional IDO seems to
be a prerequisite for MSC-mediated graft acceptance via direct
T cell suppression as well as indirect modulation of the graft
recipient’s immune system through Treg induction. Skewing of
CD4+ T cell differentiation toward a more regulatory phenotype
leads to the inhibition of T helper 17 (Th17) cell differentiation,
an effect which is partly caused by MSC-derived IDO and PGE2
(Ghannam et al., 2010; Tatara et al., 2011). The role of IL-17, pro-
duced by Th17 cells, in the onset of GvHD is still controversial.
Disease-ameliorating effects and an inductive role of ex vivo dif-
ferentiated Th17 cells have been reported (Carlson et al., 2009;
Kappel et al., 2009).
In summary, the mechanisms employed by MSC to inhibit
effector T cell proliferation overlap with the mechanisms involved
in Treg induction, yet, they do not interfere with Treg function.
IN VIVO INTERACTION BETWEEN MSC AND TREG
Whether MSC-mediated in vitro induction of Treg can be trans-
lated into the in vivo setting or even into the clinical setting remains
to be thoroughly investigated. To date little evidence from ani-
mal models exists. One of the ﬁrst in vivo studies, reporting the
induction of Treg after MSC administration, was conducted by
Gonzalez et al. (2009). Mice suffering from induced colitis were
treated with a systemic infusion of human MSC. MSC amelio-
rated the severity of colitis through the reduction of inﬂammatory
cytokines and chemokines and an increase of IL-10 concen-
trations; an overall downregulation of Th1-driven autoimmune
responses and inﬂammatory responses was observed. Although
MSC infusion impaired the expansion of Th1 cells, functional
CD4+CD25+FOXP3+ Treg were induced, conﬁrming the in vitro
MSC–Treg interplay.
A similar observation was recently made in a mouse model
of allergen-driven airway inﬂammation (Kavanagh and Mahon,
2011). Systemic administration of allogeneic mouse MSC reduced
the classical pathologies in this model as airway-mucus secre-
tion, allergen-driven lung eosinophilia, and IgE induction were
diminished. The improved pathological outcome coincided with a
higher percentage of CD4+FOXP3+ cells in both lungs and spleens
of MSC-treated mice when compared to control mice. Kavanagh
and Mahon (2011) demonstrated the importance of Treg induc-
tion by MSC in this model; after in vivo depletion of Treg with
cyclophosphamide an amelioration of the disease pathologies was
observed, which serves as further evidence that the capability
of MSC therapy to induce Treg is essential for this therapeutic
modality.
In transplantation, one of the ﬁrst models demonstrating the
in vivo induction of Treg after MSC administration was described
by Casiraghi et al. (2008). In a semi-allogeneic heart trans-
plant mouse model, pre-transplant infusion of donor-derived
MSC into the portal vein led to T cell hyporesponsiveness, pro-
longed cardiac allograft survival and expanded donor-speciﬁc
Treg expressing CD4, CD25, and FOXP3. Similar observations
were made after administration of recipient-derived MSC. Of
relevance for the translation into a clinical setting, this group
noticed that double pre-transplant infusions were more tolero-
genically effective than a single MSC infusion. In contrast,
post-transplant infusion of MSC was not effective. This suggests
that pre-exposure to donor-MSC is required or that pre-activation
of MSC might be necessary for MSC to successfully exert their
tolerogenic action when graft alloantigens challenge the recipient’s
immune system.
Further evidence that the generation of Treg by MSC con-
tributes to graft survival is provided by a kidney allograft mouse
model (Ge et al., 2010). In contrast to the ﬁndings by Casiraghi
et al. (2008), in this model intravenous administration of MSC
24 h after renal transplantation inhibited T cell proliferation. In
tolerant recipients a Th2-dominant cytokine shift was observed as
a signiﬁcant decrease of IFN-γ production was detected while IL-
4 levels were signiﬁcantly increased. Further, in recipient spleens,
frequencies of CD4+CD25+FOXP3+ T cells were higher in MSC-
treated mice. Ge et al. (2010) also found a signiﬁcant increase
of intragraft FOXP3+ cells after MSC treatment suggesting Treg
recruitment to the renal allograft. In this model, depletion of Treg
using an anti-CD25 monoclonal antibody also reversed the bene-
ﬁcial effect of MSC therapy. CD25+ T cell depletion caused graft
rejection despite MSC treatment. This study again emphasized the
importance of IDO as a mediator of MSC function. MSC derived
from IDO-knockout mice were not able to induce graft tolerance.
In a similar fashion, in vivo inhibition of IDO also abrogated the
tolerogenic effect of MSC revealing a signiﬁcant role of IDO in
MSC immunosuppressivity.
INTERACTION BETWEEN MSC AND TREG IN THE
CLINICAL SETTING
Results from preclinical studies support the plethora of in vitro
data and conﬁrm that MSC-mediated induction of Treg has func-
tional relevance in vivo. Nevertheless, to date only one clinical
study looked into this aspect of MSC therapy in a transplantation
setting (Perico et al., 2011). In this safety and clinical feasibility
study, autologous MSC were administered intravenously to two
patients 7 days after they received living-related kidney grafts.
Despite a concerning increase in serum-creatine levels after MSC
infusion, stable graft function was reported for both patients
1 year after transplantation. Both patients received induction
therapy in combination with standard maintenance immunosup-
pression. The induction regimen consisting of basiliximab and
low-dose rabbit anti-thymocyte globulin (rATG) caused a pro-
found depletion of CD4+ and CD8+ T cells in the peripheral
blood in MSC-treated and non-MSC treated patients during the
ﬁrst 30 days. In patients with MSC therapy the number of CD4+
T cells remained lower during the entire follow-up time when
compared to the number of CD4+ T cells in non-MSC patients.
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In contrast, CD8+ T cell repopulation to pre-transplant levels
was achieved in both patient groups. During T cell depletion,
the percentage of CD4+CD25+FOXP3+CD127− Treg within the
total CD4+ T cell population was reduced. However, after 30 days
the percentage of Treg increased in both MSC-treated patients.
The memory CD8+CD45RO+RA− T cells in both MSC-treated
patients remained lower than pre-transplant levels after 30 days
post-transplant despite the full recovery of total CD8+ T cell
counts around this time-point. This effect was less prominent
in patients who did not receive MSC. These ﬁndings indicate
that in comparison to the immunosuppressive medication MSC
might have an additional inhibitory effect on memory CD8+ T
cell proliferation. The combination of reduced memory CD8+ T
cells and increased percentages of Treg suggests that MSC treat-
ment leads to a more pro-tolerogenic environment. Yet, it cannot
entirely be ruled out that the observed effects are due to the
MSC treatment and not evoked by the rATG induction therapy.
More clinical experience with MSC therapy is required to obtain
conﬁdent data.
INTERACTION OF MSC AND TREG WITH
IMMUNOSUPPRESSIVE MEDICATION
Achieving graft tolerance, the long-term goal in transplanta-
tion immunology, is a major challenge. Controlling the immune
response to donor-antigen in the graft recipient is currently
accomplished by the administration of immunosuppressive drugs.
Upon the introduction of novel cellular immunotherapies they
will be applied in combination with standard immunosuppres-
sive regimens. It therefore has to be considered that these
drugs may not be permissive for MSC and/or Treg function.
Conversely, MSC and Treg may interfere with the efﬁcacy of
the agents.
In vitro studies show that MSC reduce the efﬁcacy of rapamycin
and tacrolimus and, conversely, that these immunomodulatory
agents negatively affect MSC function (Hoogduijn et al., 2008;
Buron et al., 2009). However, cumulative inhibition of effector
cell proliferation has been reported for combination therapy of
MSC with mycophenolic acid (MPA) while dexamethasone did
not inﬂuence MSC functionality. A synergistic effect of MSC and
mycophenolate mofetil (MMF), the prodrug of MPA, on pro-
longed graft survival was observed in a fully allogeneic heart
transplant mouse model (Eggenhofer et al., 2011); treatment with
MSC and cyclosporine A failed to prolong allograft survival. In
contrast to in vitro results, combination therapy of MSC and
rapamycin achieved long-term heart allograft tolerance in mice
and increased the frequency of splenic CD4+CD25+FOXP3+ T
cells (Ge et al., 2009). This ﬁnding is important as rapamycin
is currently used for the ex vivo expansion of Treg (Battaglia
et al., 2012). In renal transplant patients rapamycin led to an
increase of CD4+CD25+FOXP3+ Treg (Hendrikx et al., 2009b).
A recent study by Ma et al. (2011) indicated that in vitro
rapamycin had better synergistic effects on Treg function than
cyclosporine A and tacrolimus. Subsequent adoptive infusion of
donor-alloantigen-speciﬁc Treg in combination with low-dose
of rapamycin delayed the acute rejection of kidney allografts in
Cynomolgus monkeys. In addition, selective expansion of donor-
type CD4+CD25+FOXP3+ Treg after in vivo administration of
rapamycin in combination with IL-2 suppressed acute GvHD in
mice (Shin et al., 2011).
The interactions between both immunomodulatory cell types
and immunosuppressive drugs demonstrate that the choice of
immunosuppressive regimen will affect the outcome of cellular
therapies.
HETEROGENEITY OF THE TREG POPULATION
Recent developments in Treg research revealed a heterogeneity
of the Treg population. Apart from the well-described thymic-
derived naturally occurring CD4+CD25+CD127-FOXP3+ Treg
(nTreg), other Treg subsets have been identiﬁed. Of these the most
studied are inducedTreg (iTreg). iTreg develop fromnaïveT cells in
theperiphery and their inductionoccurs uponTcell receptor stim-
ulation,CD28 co-stimulatory signaling, and in thepresenceof IL-2
and TGF-β. Phenotypically iTreg resemble nTreg, yet, both popu-
lations can be distinguished by the methylation status of a special
locus within the Foxp3 gene (Baron et al., 2007; Wieczorek et al.,
2009). In nTreg this locus, the Treg-speciﬁc-demethylated-region
(TSDR), is fully demethylated allowing for easy transcription
while the TSDR in iTreg is methylated. Further discrimina-
tion between nTreg and iTreg may be provided by Helios, an
Icaros family transcription factor. It has been reported that nTreg
express Helios while iTreg do not (Thornton et al., 2010). Opin-
ion on this topic is divided, some groups claim that Helios
only presents an additional activation marker and is mutually
expressed by natural Treg and induced Treg (Akimova et al., 2011;
Gottschalk et al., 2012).
Apart from these two Treg subsets, non-FOXP3 expressing
CD4+ Treg have been described such as the IL-10 expressing T
regulatory (Tr) 1 cells and TGF-β expressing Th3 cells (Weiner,
2001; Roncarolo et al., 2006). Other T cells with regulatory
functions have been studied, but less extensively (Hayday andTige-
laar, 2003; Reibke et al., 2006; Ford McIntyre et al., 2008; Monteiro
et al., 2010).
These new ﬁndings have to be considered when previous Treg
work is evaluated. Further research will be required to investigate
and to distinguish the inﬂuence of MSC on Treg expansion and
Treg induction.
THE IMPORTANCE OF TREG INDUCTION BY MSC
The fate of MSC in the body after administration has been revealed
by multiple distribution studies (Barbash et al., 2003; Kraitchman
et al., 2005; Fischer et al., 2009; Assis et al., 2010; Zonta et al., 2010).
Using various types of tracking techniques it was determined that
MSC accumulate in the lung after intravenous infusion. The size of
cultured MSC is signiﬁcantly larger than the size of other immune
cells in the circulation. This might cause MSC to be trapped in the
capillaries of the lung. When MSC were administered via alterna-
tive routes, they were also found in other organs such as liver and
spleen (Shi et al., 2010). Despite the consistency of the data, the
drawback of these studies is that researchers cannot be certain that
label detection conﬁrms the presence of living MSC. Retrieved
label can originate from viable MSC, deceased MSC or possibly
phagocytosed debris of MSC.
To gain more clarity on this issue, different approaches
have been examined (Hoogduijn et al., 2011). After intravenous
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administration of labeled MSC to mice, organs were harvested,
andMSCwere isolated and re-cultured. Interestingly, labeledMSC
were found in the lung up to 24 h after infusion, but in none of
the other observed organs at any time after administration.
The apparent shortevity of MSC after infusion fortiﬁes the
importance of rapid Treg induction by MSC. While MSC are
retained in different tissues shortly after administration and sub-
sequently cleared, they “transfer” their immunomodulatory effect
to other immunosuppressive mediators. Hence, when infused
MSC are not present any longer to execute their suppressive func-
tions, increased numbers of Treg are available to enforce graft
acceptance.
CONCLUSION
Although currently prescribed drug-based immunosuppressive
regimen are effective in preventing graft rejection in transplant
patients, their main shortcoming is that their long-term applica-
tion causes malignancies, infections, and nephrotoxicity. Due to
their immunomodulatory capabilities, MSC have a high potential
to function as alternative immunosuppressive therapy possibly
with less side effects. While drugs mainly target a speciﬁc molec-
ular pathway to achieve immunomodulation, MSC appear to
have a broader effect on the patient’s immune system. Yet, fur-
ther characterization of this more global intervention by MSC
is required. Despite inﬂicting their immunosuppressive effect on
most lymphocyte subsets including T cells, MSC spare Treg. In
fact, preclinical and clinical studies indicate that MSC mediate
the expansion of natural Treg and/or the induction of novel Treg.
This becomes an important feature of MSC immunomodulation
as MSC appear to be cleared by the recipient’s immune system
shortly after infusion and hence will not be able to perform their
suppressive capacities via direct cell–cell contact or soluble factors.
Because of themultifacetedmechanismsbywhichMSCapply their
immunosuppressivity combined with the fact that they do not
impair the functionality of host Treg,MSCare very interesting can-
didates for cellular therapy in transplantation. First clinical results
in the ﬁeld of transplantation should encourage investigators to
continue their research to bring MSC therapy to the patient.
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